Institute for Myeloma and Bone Cancer Research in Los Angeles Proudly Announces Roger Townsend to join its Board of Directors as Treasurer.
Roger Townsend makes the transition to IMBCR's board of directors after serving two years on its Audit Committee.
Online, October 4, 2010 (Newswire.com) - Los Angeles, CA - The Institute for Myeloma and Bone Cancer Research is an independent, non-profit cancer research institute dedicated to finding a cure for multiple myeloma, a plasma cell cancer found in bone marrow. More than 100,000 people are diagnosed with myeloma every year and it is estimated that more than 1,000,000 are living with myeloma worldwide. IMBCR was founded in 2004 by leading myeloma researcher and oncologist, Dr. James R. Berenson whose research in both the clinic and the laboratory has spanned more than 25 years. Research conducted at IMBCR has created many of the novel-therapeutics used for myeloma patients worldwide.
Roger Townsend has over 30 years of business experience including 10 years of financial management in private industry and 20 years in public accounting. He has worked with a variety of companies, including the Automobile Club of Southern California, Hon Development Company, Stayner Development Company and Health Industries, Inc. He is a former land developer and currently is the owner of a productive avocado farm in San Diego County.
Having worked with Dr. Berenson and the IMBCR staff as a key member of its Audit Committee, Mr. Townsend is looking to expand his role as Treasurer of IMBCR's board of directors and said, "I am inspired by the work of Dr. Berenson and the researchers at IMBCR and am honored to serve as IMBCR's Treasurer."
Roger Townsend served during the Vietnam War as a LTJG in the Navy and holds a Bachelor of Arts degree in business economics from the University of California, Santa Barbara and graduate level studies in business and accounting at the University of California, Los Angeles.
About IMBCR
The Institute for Myeloma and Bone Cancer Research is headquartered in Los Angeles, CA. IMBCR research is funded in part by donations from major foundations, including the Annenberg, Skirball, Lincy and Kramer Family Foundations, FJC, (A Foundation of Philanthropic Funds), Multiple Myeloma Research Foundation and Myeloma Research Fund. Collaborative research is also sponsored by major pharmaceutical companies. IMBCR research findings have been presented at annual meetings throughout the world. IMBCR research has been published in most major oncology journals. www.imbcr.org
